Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H16N2O3 |
Molecular Weight | 212.2456 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(C)C1(CC)C(=O)NC(=O)NC1=O
InChI
InChIKey=ZRIHAIZYIMGOAB-UHFFFAOYSA-N
InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)
Barbiturates are non-selective depressants of the central nervous system. Butabarbital is one of them, which is used under brand name butisol sodium as a sedative or hypnotic. Like other barbiturates, butabarbital is capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. The mechanism of action by which barbiturates exert their effect is not yet completely understood, but is assumed, that butabarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11264449 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | BUTISOL SODIUM Approved UseBUTISOL SODIUM (butabarbital sodium tablets, USP and butabarbital sodium oral solution, USP) is indicated for use as a sedative or hypnotic. Since barbiturates appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks, use of BUTISOL SODIUM in treating insomnia should be limited to this time. Launch Date1939 |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg 4 times / day multiple, oral Recommended Dose: 15 mg, 4 times / day Route: oral Route: multiple Dose: 15 mg, 4 times / day Sources: |
unhealthy, 36 n = 16 Health Status: unhealthy Condition: low back syndrome Age Group: 36 Sex: M+F Population Size: 16 Sources: |
Disc. AE: Drowsiness... AEs leading to discontinuation/dose reduction: Drowsiness (1 patient) Sources: |
30 mg 4 times / day multiple, oral Recommended Dose: 30 mg, 4 times / day Route: oral Route: multiple Dose: 30 mg, 4 times / day Sources: |
unhealthy, adult n = 32 Health Status: unhealthy Condition: anxiety Age Group: adult Sex: M+F Population Size: 32 Sources: |
Other AEs: Sedation... |
30 mg 4 times / day multiple, oral Recommended Dose: 30 mg, 4 times / day Route: oral Route: multiple Dose: 30 mg, 4 times / day Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: anxiety Age Group: adult Sex: M+F Population Size: 40 Sources: |
Other AEs: Sedation... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Drowsiness | 1 patient Disc. AE |
15 mg 4 times / day multiple, oral Recommended Dose: 15 mg, 4 times / day Route: oral Route: multiple Dose: 15 mg, 4 times / day Sources: |
unhealthy, 36 n = 16 Health Status: unhealthy Condition: low back syndrome Age Group: 36 Sex: M+F Population Size: 16 Sources: |
Sedation | 10 patients | 30 mg 4 times / day multiple, oral Recommended Dose: 30 mg, 4 times / day Route: oral Route: multiple Dose: 30 mg, 4 times / day Sources: |
unhealthy, adult n = 32 Health Status: unhealthy Condition: anxiety Age Group: adult Sex: M+F Population Size: 32 Sources: |
Sedation | 14 patients | 30 mg 4 times / day multiple, oral Recommended Dose: 30 mg, 4 times / day Route: oral Route: multiple Dose: 30 mg, 4 times / day Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: anxiety Age Group: adult Sex: M+F Population Size: 40 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/30443785/ Page: 11.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/30443785/ Page: 11.0 |
yes |
Sample Use Guides
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
2100
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
||
|
NCI_THESAURUS |
C67084
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
204-738-6
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
C61657
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
C084833
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
125-40-6
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
CHEMBL449
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
97164-73-3
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
SUPERSEDED | |||
|
1079000
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
3018
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
BUTABARBITAL
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
Butabarbital
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
439
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
100000085806
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
P0078O25A9
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
2479
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
1152
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
DB00237
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
DTXSID2022709
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
477631
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | RxNorm | ||
|
m2779
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | Merck Index | ||
|
7137
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
3228
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY | |||
|
SUB10465MIG
Created by
admin on Fri Dec 15 17:23:02 GMT 2023 , Edited by admin on Fri Dec 15 17:23:02 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)